ABMD News and Press, ABIOMED Inc. From 01/14/22

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, February 3, 2022 at 8:00 a.m. ET. Michael...

Abiomed (NASDAQ: ABMD) announces the successful results of the first-in-human early feasibility study of the preCARDIA system. The preCARDIA system is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients by intermittently occluding the superior ven...

Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) ...

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference (virtual) on Wednesday, January 1...

Teleflex Incorporated has generally performed well over the past few years and that attractive performance resumed this year after a mixed 2020. The company's prospects are favorable, but this doesn't mean the company makes for a great buy today. In all, shares are probably more o...

The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart pumps . The study results were reviewed this morning at Transcatheter Cardiovascular Therapeutics (TCT) 2021 , the annua...

The 2021 guidelines of the European Society of Cardiology (ESC) for treatment of acute heart failure patients, including patients in cardiogenic shock, raise the recommendation level for short-term mechanical circulatory support systems such as Impella heart pumps from Class IIb...

The robust, high-quality data and clinical studies supporting the use of Abiomed's (NASDAQ:ABMD) Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2021 , the annual sc...

The following slide deck was published by Abiomed, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Abiomed, Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. ABIOMED, inc (NASDAQ: ABMD) Q2 2022 Earnings Call Oct 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: ABIOMED, inc (ABMD) Q2 2022 Earnings Call Transcript